SYG Biotech

Startup

SYG BIOTECH is a biotechnology company pioneering innovative tools and solutions to accelerate the discovery and development of next-generation therapeutic proteins. Our mission is to empower researchers and drug developers by providing rapid, efficient, and precise technologies for immune checkpoint targeting and personalized medicine. Our flagship innovation is a groundbreaking in vitro selection platform for novel binders such as VHHs, DARPins, and therapeutic peptides. This platform enables the fast identification of candidates that specifically target immune checkpoints such as PD-1 and PD-L1 – a critical pathway in immuno-oncology. By streamlining the early discovery phase, we help reduce development time and improve therapeutic precision. In addition, we have developed a user-friendly rapid detection kit for PD-1, PD-L1, and their inhibitors, enabling researchers to easily analyze these biomarkers in the lab. This solution opens new avenues for personalized immunotherapy strategies, biomarker validation, and inhibitor screening. At SYG BIOTECH, we are committed to pushing the boundaries of science to improve global health outcomes. Our dual scientific and business expertise allows us to bridge innovation and application – from lab bench to clinic